Annotation Detail

Information
Associated Genes
EGFR
Associated Variants
EGFR EXON 19 DELETION ( ENST00000275493.7 )
EGFR EXON 19 DELETION ( ENST00000275493.7 )
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib or erlotinib (38 versus 17 months; P = 0.04).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/413
Gene URL
https://civic.genome.wustl.edu/links/genes/19
Variant URL
https://civic.genome.wustl.edu/links/variants/133
Rating
4
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Gefitinib,Erlotinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
16818686
Drugs
Drug NameSensitivitySupported
ErlotinibSensitivitytrue
GefitinibSensitivitytrue